Medicinal Cannabis Program Fees and Charges Review

Overview

On 24 December 2021 several changes to the Narcotic Drugs Act 1967 came into effect, including the introduction of a single licence model for cultivation, production and/or manufacture activities. At this time the Office of Drug Control (ODC) also implemented simpler permit processes and administrative reforms to reduce regulatory burden.

Following these reforms, the existing cost model was also reviewed, including the level at which fees and charges are set. In doing so it has become evident that some regulatory effort was not included in the existing fees and charges for the Medicinal Cannabis Program (the Program). The outcome of the review has informed the Australian Government’s consideration of the costs to be recovered for the regulatory effort for the Program.

The Consultation Paper summarises the findings of the fees and charges review, including the proposed changes, and seeks further feedback from stakeholders.

Why your views matter

We are seeking your input on whether you support some or all of the proposed changes to the medicinal cannabis fees and charges. Submissions may address any, or all of the matters contained in the Consultation Paper.

The ODC is particularly interested in your feedback on the:

• Proposed Licence Fee Structure
• Proposed Permit Fee Structure
• Proposed Inspection and Annual Charge Structure
• Proposed Options for Fee and Charges

In providing feedback, please provide examples of circumstances in which you think the application of these fees and charges may be problematic, or how the proposed fees or charges would be applied to your specific circumstances.